Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House FDA Funding Plan Is Below Senate Proposal

This article was originally published in The Gray Sheet

Executive Summary

The House would cut FDA funding next year under a bill approved by a subcommittee last week.

You may also be interested in...



Congress Enters Final Stages On FDA Reform Bill

Legislative leaders say they remain on track to send FDA user fee reauthorization and reform legislation for the president’s signature by the end of June following House passage of bill.

Senate Panel Approves FDA Appropriations, With Strong Words On Agency IT Systems

The Senate Appropriations Committee approves a $3.9 billion budget for the agency in fiscal 2013, including $319 million in federal funding for device activities.

User Fee Factor: FDA Relies On Industry Funds To Bankroll 2013 Device Budget Increase

FDA’s device appropriations from Congress would slightly decline next year under the president’s 2013 funding request, though factoring in industry user fees provides an overall budget increase.

Related Content

Topics

UsernamePublicRestriction

Register

MT031292

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel